First Parkinson's patient dosed with MTX325, a pill designed to clear faulty mitochondria
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Most Parkinson's drugs replace or mimic dopamine and ease symptoms without slowing the disease. MTX325 is built on a different idea: help neurons throw out their broken mitochondria faster. On October 15, 2026, Mission Therapeutics announced that the first patient in its Phase 1b study of the drug has been dosed at Royal Liverpool University Hospital in the UK.
MTX325 blocks USP30, an enzyme that sits on mitochondria and normally puts the brakes on mitophagy — the cell's quality-control process for removing damaged mitochondria. Releasing that brake is intended to improve mitochondrial quality, support cell health, and reduce inflammation in the brain regions that degenerate in Parkinson's.
What will the Phase 1b study measure?
The MTX325-101 study is a proof-of-mechanism trial: it will assess safety and tolerability and use a wide range of biomarkers and imaging measures to test whether the drug is engaging its biology in patients. About 36 people with mild to moderate idiopathic Parkinson's are expected to enroll across sites in the UK, Europe, and Australia, and the company anticipates a data readout in late 2027. The study follows a completed Phase 1a single- and multiple-dose study in healthy volunteers, in which the company reported high penetration into the central nervous system, with a PET study confirming distribution into brain tissue.
Why do researchers think USP30 is worth blocking?
The target has genetic backing. In a Nature Communications study, deleting or inhibiting USP30 protected dopamine-producing neurons in a mouse model of Parkinson's, and MTX325 produced a similar effect in the same model. In preclinical work the company also reported increased mitophagy and beneficial effects on alpha-synuclein accumulation — the protein that clumps in Parkinson's brains — and on the nigrostriatal dopamine neurons that are lost as the disease progresses.
What should patients make of this milestone?
A first patient dosed is a starting gun, not a result. Phase 1b can show whether the drug is safe in patients and whether biomarkers move the way the mechanism predicts; it cannot show whether MTX325 slows Parkinson's — that would require larger, longer trials with clinical endpoints. The honest timeline is the company's own: a proof-of-mechanism readout is not expected until late 2027.
Where the evidence stands
- Established: USP30 restrains mitophagy, and genetic deletion or inhibition of USP30 protected dopaminergic neurons in a mouse Parkinson's model (Nature Communications); defective mitochondrial quality control is a recognized feature of Parkinson's biology.
- Preliminary: Company-reported: MTX325 completed Phase 1a dosing in healthy volunteers with high CNS penetration and PET-confirmed brain distribution, and the first Parkinson's patient has now been dosed in Phase 1b (36 participants planned; readout anticipated late 2027).
- Absent: Any evidence in people that MTX325 improves symptoms, slows progression, or changes the course of Parkinson's disease.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.